Application of leukemia inhibitory factor in the preparation of drugs for the treatment of corneal endothelial disease
By using leukemia inhibitors as drugs for corneal endothelial lesions, the problem of insufficient drugs for corneal endothelial lesions is solved through the form of vitreous injection, the recovery of corneal endothelial cell function and the ejaculation of edema is achieved, and the need for corneal transplant surgery is delayed. Significantly improves the visual recovery effect.
Patent Information
- Application Number
- CN202311494893.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-11-10
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2043-11-10
AI Technical Summary
The existing technology lacks effective drug treatment methods to deal with corneal endothelial lesions, which leads to patients who need to wait until the corneal endothelial function is lost before considering corneal transplantation, and may face the problems of rejection and failure of the implant after corneal transplantation.
Leukemia inhibitors are used as drugs to treat corneal endothelial lesions. Through the form of vitreous injection, the function of residual corneal endothelial cells is enhanced, the regression of corneal edema and visual function recovery is promoted, and the timing of transplantation surgery is delayed.
Leukemia inhibitors can accelerate the repair of corneal endothelial cells, prolong corneal transparency time, reduce edema, postpone transplant surgery, and significantly improve the effect of vision recovery.
Smart Images

Figure CN117379536B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medical technology, and specifically relates to the application of leukemia inhibitory factor in preparing a drug for treating corneal endothelial lesions. Background Art
[0002] In China, there are approximately 4 million patients who are blinded by corneal diseases, and there are 100,000 to 200,000 new cases each year. Corneal blindness has become the second leading cause of blindness in my country, and many of these patients have lesions in the corneal endothelial cell layer. Corneal endothelial cells are located in the innermost layer of the cornea, and their main function is to maintain the transparency of the cornea through the active ion pumps and barrier functions on their surface. Human corneal endothelial cells cannot regenerate in the body. Once damaged or diseased, they can only rely on the expansion and migration of adjacent cells to fill the damaged area. The density of corneal endothelial cells at birth is about 7500 / mm 2 As age increases, the number of cells gradually decreases, reaching about 2000-3000 / mm in old age. 2 When the density of corneal endothelial cells drops to 500 / mm 2 When it is around, the function of the corneal endothelial cells cannot meet the needs of regulating the water content of the cornea, resulting in corneal edema and subsequent vision loss.
[0003] Corneal endothelial disease can be caused by a variety of reasons, including mechanical damage such as surgical operation (called bullous keratopathy); congenital factors such as congenital corneal endothelial dystrophy, iridocorneal endothelial syndrome (ICE syndrome), posterior polymorphic corneal endothelial dystrophy, Fuchs corneal endothelial dystrophy, etc.; infectious factors such as viral corneal endotheliitis. Early analysis of the cause through slit lamp and medical history, and appropriate treatment can improve the patient's vision and even avoid surgical treatment (such as viral corneal endotheliitis).
[0004] At present, there is no effective drug treatment for corneal endothelial diseases except viral corneal endotheliitis. They can only be allowed to develop until the corneal endothelial function is completely lost and corneal edema occurs, and corneal transplantation surgery is performed. At present, corneal endothelial transplantation has become the best surgical procedure for treating corneal endothelial decompensation, which is characterized by low surgical risk, small postoperative astigmatism and rapid visual recovery. In 2014, a total of 46,513 corneal transplants were performed in the United States, of which corneal endothelial transplants accounted for 55.9% of the total number of surgeries, indicating that it has become the dominant procedure for corneal transplantation. In recent years, the surgical methods of corneal endothelial transplantation have been continuously updated, with smaller incisions, thinner grafts, and better visual recovery. In Europe, the United States and other countries, the latest surgical method, Descemet's membrane keratomileusis (DMEK), is becoming more and more the main surgical option. The thickness of the graft in this surgical method is only a dozen microns. Because the graft is thinner and more in line with the anatomical structure, the postoperative vision is better. However, it requires patients to have a good anterior chamber structure and a complete lens-iris septum.
[0005] Fuch's corneal endothelial dystrophy, the preferred treatment in the past was DSAEK or DMEK. But at the same time, this also brings a series of long-term problems that corneal transplantation must face, such as postoperative rejection and graft failure. However, a series of recent studies have shown that simple Descemet's membrane tearing without graft transplantation is also very effective in treating Fuch's corneal endothelial dystrophy. However, this surgical method has not yet been carried out in my country, and whether it is suitable for Chinese patients and its postoperative effects still need further verification. The treatment of patients with iridocorneal endothelial syndrome (ICE) is also a difficult problem that troubles ophthalmologists. Since there is no treatment for the cause, current treatment focuses on controlling intraocular pressure and maintaining corneal transparency. The latest studies have shown that 50% of patients need surgery to control intraocular pressure, and 14% of patients need corneal transplantation. The current surgery is mainly DSAEK, and there are also reports of DMEK surgery. However, the problems of intraocular pressure and iris after surgery still exist, and the graft failure rate is still significantly higher than that of non-ICE patients. Therefore, there is still a need to design a better surgical plan for these patients.
[0006] Leukemia inhibitory factor is a cytokine with multiple functions, but its most important application is to maintain the undifferentiated state of embryonic stem cells. LIF expression has been found in activated T cells, monocytes, glial cells, liver fibroblasts, bone marrow stromal cells, embryonic stem cells, thymic epithelial cells and other cells. Its homology is 78-94%. The main effects include: (1) regulating cell proliferation, differentiation and phenotype; (2) inhibiting lipoprotein lipase activity and reducing the uptake of free fatty acids by 3T3-L1 adipocytes; (3) promoting bone reabsorption, which may be mediated by LIF stimulating osteoblasts to synthesize prostaglandins; (4) inducing the production of acute phase proteins in the liver. The prior art has not reported that leukemia inhibitory factor can be used as a drug for the treatment of corneal endothelial lesions. Summary of the invention
[0007] Based on the above reasons, the present invention proposes the use of leukemia inhibitory factor in the preparation of a drug for treating corneal endothelial disease. Specifically, in order to achieve the purpose of the present invention, the present invention intends to adopt the following technical solutions:
[0008] One aspect of the present invention relates to the use of leukemia inhibitory factor in the preparation of a drug for treating corneal endothelial lesions.
[0009] In a preferred embodiment of the present invention, the drug is an injection or an eye drop.
[0010] In a preferred embodiment of the present invention, the injection solution is a vitreous cavity injection solution.
[0011] In a preferred embodiment of the present invention, the drug for treating corneal endothelial disease is used to rapidly reduce corneal edema and / or restore visual function. Beneficial Effects
[0012] The present invention can enhance the function of the remaining corneal endothelial cells through leukemia inhibitory factor, prolong the corneal transparency time of the corneal endothelial cells on the verge of decompensation, delay the timing of corneal transplantation surgery; accelerate the repair of corneal endothelial cells in the damaged area, quickly reduce corneal edema, and restore visual function. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] Figure 1 :The results of the study on the effect of leukemia inhibitory factor (LIF) injection into the vitreous cavity of rabbit eyes after scraping corneal endothelial cells; the first row and the second row are the diffuse light and slit photography of eyes injected with LIF, and the third row and the fourth row are the diffuse light and slit photography of eyes not injected. The first column is before surgery; the second column is the postoperative period, the central blue area is the trypan blue-stained corneal scraping area, with a diameter of 7.5mm; the third to ninth columns are the 1st to 7th days after surgery, respectively. It can be clearly seen that the corneal edema of the LIF injection group was significantly lighter than that of the control group and the edema subsided rapidly.
[0014] Figure 2 : Curve of corneal thickness changing with time at the site of the heaviest edema.
[0015] Figure 3 : Transmission electron microscopy results showed that the morphology of organelles in the experimental group was good, there was no fluid accumulation between cells, and glycogen granules were visible; the endoplasmic reticulum of the control group was edematous, a large amount of fluid was visible between cells, and some mitochondria were edematous. DETAILED DESCRIPTION
[0016] In order to further understand the present invention, the technical solutions in the embodiments of the present invention will be clearly and completely described below in combination with the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0017] Unless otherwise specified, the reagents involved in the embodiments of the present invention are all commercially available products and can be purchased through commercial channels.
[0018] Example 1
[0019] Twelve New Zealand white rabbits were anesthetized by Shutai, and the ocular surface was anesthetized with oxybuprocaine hydrochloride. The anterior chamber was perfused with balanced salt solution. The range of corneal endothelial cell removal was marked by trephine. The corneal endothelial cells were scraped along the marked line. Trypan blue staining was used to determine whether the endothelial removal was complete. The incision was sutured with 10-0 sutures. The control group (6 rabbits) was injected with 50 μl of balanced salt solution into the vitreous cavity, and the experimental group (6 rabbits) was injected with 50 μl of balanced salt solution containing 125 μg of human LIF (amino acid sequence: ITPVNATCAIRHPCHNNLMNQIRSQLAQLNGSANALFILYYTAQGEPFPNNLDKLCGPNVTDFPPFHANGTEKAKLVELYRIVVYLGTSLGNITRDQKILNPSALSLHSKLNATADILRGLLSNVLCRLCSKYHVGHVDVTYGPDTSGKDVFQKKKLGCQLLGKYKQIIAVLAQA). Photographic examinations were performed every day after surgery. In experiments, it was observed that intravitreal injection of leukemia inhibitory factor in rabbits with corneal endothelial decompensation could make the cornea recover more quickly and reduce edema. Figure 1 shown.
[0020] Optical coherence tomography was used to measure corneal thickness, and the thickness of the LIF injection group was significantly lower than that of the control group. Figure 2 shown.
[0021] Transmission electron microscopy was used to observe the results. Figure 3 As shown, there was no intercellular fluid accumulation in the experimental group and the intracellular organelle structure was normal, while intercellular fluid accumulation and edema of the endoplasmic reticulum and Golgi apparatus were observed in the control group.
[0022] The above describes the preferred embodiments of the present invention, but it is not intended to limit the present invention. Those skilled in the art may make improvements and changes to the embodiments disclosed herein without departing from the scope and spirit of the present invention.
Claims
1. Use of leukemia inhibitory factor in the preparation of a drug for treating corneal endothelial disease, wherein the amino acid sequence of the leukemia inhibitory factor is the amino acid sequence shown in SEQ ID No. 1, and the drug for treating corneal endothelial disease is used to quickly reduce corneal edema and / or restore visual function.
2. The use according to claim 1, wherein the medicine comprises an injection or an eye drop.
3. The use according to claim 2, wherein the injection is a vitreous cavity injection, and the eye medicine comprises eye drops, eye gel or eye ointment.
